Free Trial
NASDAQ:SYBX

Synlogic Q4 2023 Earnings Report

Synlogic logo
$1.40 +0.04 (+2.87%)
Closing price 08/8/2025 03:56 PM Eastern
Extended Trading
$1.40 +0.00 (+0.07%)
As of 08/8/2025 05:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Synlogic EPS Results

Actual EPS
-$1.71
Consensus EPS
-$1.11
Beat/Miss
Missed by -$0.60
One Year Ago EPS
N/A

Synlogic Revenue Results

Actual Revenue
$2.77 million
Expected Revenue
$2.71 million
Beat/Miss
Beat by +$60.00 thousand
YoY Revenue Growth
N/A

Synlogic Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Tuesday, March 19, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Synlogic's Q3 2025 earnings is scheduled for Thursday, August 14, 2025

Synlogic Earnings Headlines

Synlogic (SYBX) Expected to Announce Quarterly Earnings on Thursday
When the levee breaks
The U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was projected. According to Porter Stansberry, this is panic-level borrowing… and a clear sign we’re nearing America’s financial breaking point. In his latest emergency briefing, Porter outlines why the cracks in our system are widening fast—and how Trump’s policies may be accelerating the collapse. More importantly, he reveals three moves you can make now to protect and potentially grow your wealth before the levee breaks.
Synlogic Reports Q3 2024 Financial Outcomes
See More Synlogic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Synlogic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Synlogic and other key companies, straight to your email.

About Synlogic

Synlogic (NASDAQ:SYBX), a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

View Synlogic Profile

More Earnings Resources from MarketBeat